CDP 870: Phase II studies in Crohn’s disease

• 292 active Crohn’s patients

  • 3 dosage groups + placebo
  • 3 doses / 12 weeks (sc)
  • Clinical response: CDAI ? 100 points or remission
  • Multiple end-points

Previous slide

Next slide

Back to first slide

View graphic version